In a cohort of BNT162b2 (Pfizer–BioNTech) mRNA vaccine recipients (n= 1,090), we
observed that spike-specific IgG antibody levels and ACE2 antibody binding inhibition …

The Pfizer/BioNTech (BNT162b2) SARS-CoV-2 mRNA vaccine demonstrated 95% efficacy
after 2 doses during clinical trials. 1 There are reports that individuals with previous SARS …

The BNT162b2 mRNA vaccine is highly effective against SARS-CoV-2. However,
apprehension exists that variants of concern (VOCs) may evade vaccine protection, due to …

Although antibody levels progressively decrease following SARS-CoV-2 infection, the
immune memory persists for months. Thus, individuals who naturally contracted SARS-CoV …

The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses
administered three weeks apart. However, some public health authorities spaced these …

ABSTRACT Background SARS-CoV-2 mRNA vaccines have proven high efficacy, however,
limited data exists on the duration of immune responses and their relation to age and side …

An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and …

As SARS-CoV-2 has been circulating for over a year, dozens of vaccine candidates are
under development or in clinical use. The BNT162b2 mRNA COVID-19 vaccine induces …

Two COVID-19 mRNA vaccines, BNT162b2 (ie, Pfizer/BioNTech) and mRNA-1273 (ie,
Moderna), were approved via the US Food and Drug Administration Emergency Use …

The advent of COVID-19 vaccines will play a major role in helping to end the pandemic that
has killed millions worldwide. Vaccine candidates have demonstrated robust humoral …